Bifidobacterium breve MAK40B22B and Increased Fecal Bifidobacteria Levels

• Effect of Bifidobacterium breve M-16V Supplementation on Fecal Bifidobacteria in Preterm Neonates - A Randomised Double Blind Placebo Controlled Trial

  • 2014-03-03
  • RCT · n = 159
  • PLoS ONE 9(3)
  • • S. Patole
    • A. Keil
    • An-Yi Chang
    • E. Nathan
    • D. Doherty
    • K. Simmer
    • Meera Esvaran
    • P. Conway

  • PubMed: 24594833
  • DOI: 10.1371/journal.pone.0089511

  10 Insights on

  • Increased Fecal Bifidobacteria Levels

  • High evidence
  • Highly Cited
  • Rigorous Journal
  • Infants

  The proportion of neonates with detectable B. breve increased significantly post intervention: Placebo: [S1:2/66 (3%), S2: 25/66 (38%), p<0.001] Probiotic: [S1: 29/74 (40%), S2: 67/74 (91%), p<0.001]. Median S1 B. breve counts in both groups were below detection (<4.7 log cells x g(-1)), increasing significantly in S2 for the probiotic group (log 8.6) while remaining <4.7 log in the control group (p<0.001).

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes